18:10 , Nov 9, 2018 |  BC Week In Review  |  Company News

Genentech seeks to block JHL from using trade secrets

Genentech Inc. is asking a federal court to block JHL Biotech Inc. (Zhubei, Taiwan) from making and selling products the company claims benefited from its proprietary information, following the indictment of three former Genentech employees...
00:40 , Nov 8, 2018 |  BC Extra  |  Company News

Genentech seeks to block JHL from using trade secrets

Genentech Inc. is asking a federal court to block JHL Biotech Inc. (Zhubei, Taiwan) from making and selling products the company claims benefited from its proprietary information, following the indictment of three former Genentech employees...
20:04 , Nov 2, 2018 |  BC Week In Review  |  Financial News

Twist raises $70M in NASDAQ IPO

Twist Bioscience Corp. (NASDAQ:TWST) raised $70 million in an IPO of 5 million shares at $14 on Oct. 31. The price values the DNA synthesis company at $372.5 million. Twist had proposed to sell 5...
00:06 , Sep 28, 2018 |  BC Innovations  |  Emerging Company Profile

GDF11 against aging

Harvard University spinout Elevian Inc. is developing a regenerative platform around GDF11 to treat age-related diseases, including Alzheimer's disease. The company, which emerged from stealth on Sept. 6, aims to modulate the protein’s pathway with...
18:56 , Aug 31, 2018 |  BC Week In Review  |  Company News

Gritstone files for IPO, forges deal with bluebird

Gritstone Oncology Inc. (Emeryville, Calif.) filed for an IPO on NASDAQ and announced a deal with bluebird bio Inc. (NASDAQ:BLUE) to develop cell therapies using natural T cell receptors (TCRs) against tumor-specific targets. Gritstone filed...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
20:37 , Aug 23, 2018 |  BC Extra  |  Company News

Gritstone files for IPO, forges deal with bluebird

Gritstone Oncology Inc. (Emeryville, Calif.) filed for an IPO on NASDAQ and announced a deal with bluebird bio Inc. (NASDAQ:BLUE) to develop cell therapies using natural T cell receptors (TCRs) against tumor-specific targets. Gritstone filed...
15:35 , Jun 12, 2018 |  BC Innovations  |  Translation in Brief

A glioblastoma feature story

The Ivy Glioblastoma Atlas Project has added anatomically based expression patterns to the growing body of transcriptional atlases, and the results are being used to pinpoint intratumor regions as therapeutic targets. Led by the Allen...
21:46 , Apr 25, 2018 |  BC Innovations  |  Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in...
18:52 , Mar 15, 2018 |  BC Innovations  |  Tools & Techniques

Shared burden

Having learned their lesson with PD-L1, companies are collaborating on assay standards for tumor mutation burden -- a likely contender for the next major biomarker in immuno-oncology. A Friends of Cancer Research-led consortium of pharmas...